From Uric Acid Metabolism to Gouty Inflammation: Model Strategies for Preclinical Research

Bridging the Species Gap in Hyperuricemia and Gout Research: Humanized Mouse Models for Translational Drug Discovery

Hyperuricemia and gout are becoming increasingly important areas in metabolic and inflammatory disease research. With changes in diet, lifestyle, and metabolic health worldwide, the prevalence of hyperuricemia has continued to rise, and gout is now affecting a growing and younger patient population. Beyond acute joint pain, hyperuricemia and gout are closely associated with cardiovascular disease, chronic kidney disease, and metabolic syndrome, making them clinically relevant far beyond rheumatology alone ^[1].

Figure 1. Diagnostic criteria and prevalence for hyperuricemia in each country/area^[1]

Current clinical treatment options include urate-lowering agents such as allopurinol and febuxostat, as well as anti-inflammatory drugs such as colchicine for acute gout flares. However, important therapeutic limitations remain. Some patients experience hypersensitivity reactions, hepatic or renal toxicity, cardiovascular risks, inadequate response, or poor long-term disease control. These unmet needs continue to drive the development of safer, more selective, and more effective next-generation urate-lowering and anti-inflammatory therapies.

Figure 2. Inducing factors and therapeutic strategies for hyperuricemia^[1].

Precision drug discovery relies heavily on animal models that highly replicate human disease characteristics. However, a massive "species gap" exists between humans and rodents regarding uric acid metabolism.

To help researchers overcome this developmental barrier, Cyagen has launched a comprehensive core mouse model matrix for hyperuricemia and gout research. This portfolio spans from the foundational disease model (Uox KO mice) to fully humanized models targeting uric acid production (XDH), uric acid excretion (URAT1), and the gouty inflammatory cascade (NLRP3, IL1B). Additionally, Cyagen has innovatively developed dual-gene edited composite models, such as Uox KO/huURAT1 and Uox KO/huXDH.

Table 1. Cyagen mouse model portfolio for hyperuricemia and gout research.

Hyperuricemia and Gout: From Metabolic Imbalance to Inflammatory Cascade

Hyperuricemia results from excessive uric acid production, insufficient uric acid excretion, or both. When serum urate reaches supersaturation, monosodium urate crystals can deposit in joints and surrounding tissues, triggering the intense inflammatory response known as gout ^[2].

This disease process can be broadly divided into two major therapeutic directions. The first is urate lowering, which targets either uric acid production or renal urate handling. The second is inflammation control, particularly the downstream inflammatory cascade triggered by monosodium urate crystals. Cyagen’s model strategy is designed around these disease-relevant mechanisms.

The Foundation of Disease Modeling: the Uox KO Mouse

Why is it exceptionally difficult for wild-type mice to spontaneously develop hyperuricemia? The answer lies in Urate oxidase (UOX). Humans are highly susceptible to high uric acid because, during our evolution approximately 20 million years ago, mutations in the human ancestor's UOX gene rendered it a non-functional pseudogene [3-5]. Without functional UOX protein, the final product of human purine metabolism is the poorly water-soluble uric acid. Conversely, mice possess highly active UOX, which rapidly oxidizes and degrades uric acid into highly water-soluble allantoin for excretion, thereby maintaining extremely low serum uric acid levels.

Figure 3. Phylogenetic relationship of mammalian urate oxidase genes^[3].

Using standard wild-type mice to screen urate-lowering drugs introduces severe mechanistic biases. To perfectly replicate the physiological baseline of the human "uricase deficiency," the Uox KO mouse was developed. By knocking out the Uox gene, these mice completely lose the ability to degrade uric acid, resulting in a significant spike in serum uric acid levels and the spontaneous formation of hyperuricemia and urate nephropathy phenotypes ^[6-7]. The Uox KO mouse is widely recognized as a "gold standard" disease model that closely mirrors human uric acid metabolism, providing an indispensable in vivo environment for evaluating cutting-edge urate-lowering therapies ^[6-7].

Figure 4.Validation data of Cyagen’s Uox KO mouse

Targeting Uric Acid Production: XDH/XOR and huXDH Mice

Xanthine oxidoreductase (XOR) is a molybdo-flavoenzyme that exists in two forms: the reduced form, xanthine dehydrogenase (XDH), or the oxidized form, xanthine oxidase (XO). XDH can be converted to XO via reversible sulfhydryl oxidation or irreversible proteolytic modification. In the process of uric acid synthesis, XDH is a crucial rate-limiting enzyme. It catalyzes the oxidation of hypoxanthine to xanthine, and further oxidizes xanthine to uric acid, effectively acting as the central "choke point" for endogenous uric acid synthesis ^[8-10]. First-line clinical ULTs (such as Febuxostat) act by potently inhibiting XDH/XO activity, reducing uric acid production at the source ^[8-11].

Figure 5. Uric acid synthesis pathway catalyzed by XOR

Although mouse and human XDH has some functional similarities, species differences in base/amino acid sequences and protein spatial conformation mean that innovative, highly selective small molecule inhibitors or small nucleic acid drugs designed against human XDH often face "acclimatization" issues in wild-type mice, resulting in significantly compromised binding affinity or efficacy. Cyagen’s huXDH humanized mice(Product No.：C001586）specifically express the full-length human XDH gene (including upstream and downstream UTR regions) and humanized XDH protein, making them an exceptional tool for screening and evaluating next-generation human-targeted XDH therapeutics. The Uox KO/huXDH dual-model further achieves a powerful combination of a "hyperuricemia pathological background + human-specific target".

Figure 6. Validation data of huXDH mouse

Promoting Uric Acid Excretion: URAT1 and huURAT1 Mice

Clinical studies demonstrate that over 90% of HUA patients suffer from impaired renal uric acid excretion [12]. Approximately 90% of the uric acid filtered by the glomeruli in the human body is reabsorbed back into the blood by the proximal convoluted tubule. During this reabsorption process, Urate Transporter 1 (URAT1, encoded by the SLC22A12 gene), located on the brush border of renal tubular epithelial cells, plays the most decisive role, handling about 90% of renal uric acid reabsorption [12-13]. Therefore, inhibiting URAT1 effectively opens the "floodgates" for uric acid excretion. It is the core target for uricosuric drugs like Lesinurad and Dotinurad.

Figure 7. URAT1 transporter mechanism

Human and mouse URAT1 differ not only in homology but exhibit vast disparities in substrate affinity and inhibitor sensitivity. The binding affinity of rodent URAT1 to uric acid is only 14% to 20% of human URAT1, and it shows an extremely weak response to URAT1 inhibitors [13-15]. Evaluating URAT1 inhibitors in wild-type mice is practically futile. To accurately assess the pharmacokinetics and pharmacodynamics of human-targeted URAT1 inhibitors (URICs), Cyagen’s huURAT1 humanized mice (Product No.：C001704）clear the path. Furthermore, to validate uricosuric efficacy in animals exhibiting a high uric acid phenotype, the dual-gene edited composite model (Uox KO/huURAT1) is highly recommended to obtain the most clinically translatable data.

Figure 8. Validation data of huURAT1 mouse

Modeling Gouty Inflammation: NLRP3 Inflammasome, IL-1β, and Humanized Inflammatory Pathway Models

When hyperuricemia triggers a gout flare, patients face an acute and intense joint inflammatory storm. The core mechanism of this process is as follows: MSU crystals deposited in the joint cavity are phagocytosed by macrophages, which triggers and activates the intracellular NLRP3 inflammasome. This subsequently activates Caspase-1, which cleaves the inactive pro-interleukin-1β (pro-IL-1β) into the mature inflammatory cytokine IL-1β and releases it extracellularly ^[2]. IL-1β is the "chief culprit" driving the redness, swelling, heat, and pain of gouty arthritis, initiating a cascading amplification effect that recruits massive neutrophil infiltration.

Figure 9. Mechanisms of gout initiation and resolution^[2].

Currently, targeting the NLRP3 inflammasome pathway or directly neutralizing IL-1β (e.g., Canakinumab) is considered a highly promising frontier for treating refractory gout and preventing gout flares ^[2]. Because macromolecular biological drugs and highly specific small molecules are subject to strict species cross-recognition limitations, Cyagen’s huNLRP3(Product No.：C001616) and huIL1B humanized mice (Product No.：C001791)provide a perfectly matched target environment for the screening of such anti-inflammatory agents. Inducing MSU arthritis in these models allows for incredibly precise in vivo evaluation of the anti-inflammatory efficacy of innovative drugs targeting human NLRP3 or IL-1β.

Figure 10. Validation data of huNLRP3 mouse

Conclusion: Building a More Translational Model Strategy for Hyperuricemia and Gout Drug Discovery

Hyperuricemia and gout drug development requires models that reflect both human uric acid metabolism and human-specific drug targets. From Uox knockout mice that establish a human-like uricase-deficient metabolic background, to huXDH and huURAT1 models that support target-specific pharmacology, and huNLRP3/huIL1B models that enable inflammatory pathway evaluation, Cyagen’s model portfolio is designed to support multiple stages of preclinical research.

For researchers developing small-molecule inhibitors, nucleic acid therapeutics, uricosuric agents, or anti-inflammatory biologics, choosing the right animal model can directly influence the interpretability and translational value of preclinical data.

Cyagen provides genetically engineered and humanized mouse models for hyperuricemia and gout research, supporting target validation, pharmacodynamic evaluation, and customized preclinical study design.

Contact Cyagen to learn more about model availability, phenotype data, and tailored study solutions for hyperuricemia and gout drug discovery.

Reference

[1] Du L, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):212.

[2] Dalbeth N, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69.

[3] Kratzer JT, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A. 2014;111(10):3763-8.

[4] Wu XW, et al. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci U S A. 1989;86(23):9412-6.

[5] de Lima Balico L, et al. Genomic insertion of ancestral uricase into human liver cells to determine metabolic consequences of pseudogenization. Sci Rep. 2025;15(1):26093.

[6] Cheng W, et al. Pathogenesis, animal models and pharmacological treatments of hyperuricemia: A systematic review. Biomed Pharmacother. 2026;195:119011.

[7] Lu J, et al. Knockout of the urate oxidase gene provides a stable mouse model of hyperuricemia associated with metabolic disorders. Kidney Int. 2018;93(1):69-80.

[8] Cicero AFG, et al. Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. Medicina (Kaunas). 2021;57(1):58.

[9] Furuhashi M, et al. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab. 2020;319(5):E827-E834.

[10] Lee Y, et al. Efficacy of Xanthine Oxidase Inhibitors in Lowering Serum Uric Acid in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. J Clin Med. 2022;11(9):2468.

[11] Bortolotti M, et al. Xanthine oxidoreductase: One enzyme for multiple physiological tasks. Redox Biol. 2021;41:101882.

[12] Song D, et al. A brief review of urate transporter 1 (URAT1) inhibitors for the treatment of hyperuricemia and gout: Current therapeutic options and potential applications. Eur J Pharmacol. 2021;907:174291.

[13] Tan PK, et al. Mechanism of high affinity inhibition of the human urate transporter URAT1. Sci Rep. 2016;6:34995.

[14] Suo Y, et al. Molecular basis of the urate transporter URAT1 inhibition by gout drugs. Nat Commun. 2025;16(1):5178.

[15] Tan PK, et al. Coevolution of URAT1 and Uricase during Primate Evolution: Implications for Serum Urate Homeostasis and Gout. Mol Biol Evol. 2016;33(9):2193-200.